Advice
in the absence of a submission from the holder of the marketing authorisation:
ruxolitinib (Jakavi®) is not recommended for use within NHSScotland.
Indication under review: for the treatment of:
- patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids
- patients aged 12 years and older with chronic graft versus host disease who have inadequate response to corticosteroids
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice620KB (PDF)
Medicine details
- Medicine name:
- ruxolitinib (Jakavi®)
- SMC ID:
- SMC2498
- Indication:
for the treatment of:
- patients aged 12 years and older with acute graft versus host disease who have inadequate response to corticosteroids
- patients aged 12 years and older with chronic graft versus host disease who have inadequate response to corticosteroids
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 June 2022
Additional notes
SMC advice relating to use in acute graft versus host disease has been superseded by SMC2750. SMC advice relating to patients with chronic graft versus host disease remains valid.